Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 7/2022

01.07.2022 | Original Paper

Expression of proliferation-related genes in BM-MSC-treated ALL cells in hypoxia condition is regulated under the influence of epigenetic factors in-vitro

verfasst von: Xiaoyu Yang, Yan Wang, Heshu Sulaiman Rahman, Talar Ahmad Merza Mohammad, Amin Daei Sorkhabi, Stanislav Evgenievich Korsakov, Lakshmi Thangavelu, Ali Adili, Aila Sarkesh, Rozita Tamjidifar, Hossein Saeedi, Ramin Aslaminabad, Saeed Tarzi, Morteza Akbari

Erschienen in: Medical Oncology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Mesenchymal stem cells affect ALL cell biology under hypoxic conditions. We studied survival, proliferation, expression, and promoter methylation levels of essential genes involved in expanding MOLT-4 cells co-cultured with BM-MSC under the hypoxic condition. Here, MOLT-4 cells were co-cultured with BMMSCs under hypoxic conditions. First, the apoptosis rate was evaluated by Flow cytometry. Then, MOLT-4 cells’ proliferation rate was assessed using MTT assay, and the expressions and methylation rates of genes were determined by qRT-PCR and MS-qPCR, respectively. The results showed that although MOLT-4 cells proliferation and survival rates were reduced under hypoxic conditions, this reduction was not statistically significant. Also, we showed that hypoxic conditions caused upregulation of candidate genes and affected their methylation status. Besides, it was revealed that Pontin was downregulated, while KDM3A, SKP2, and AURKA had an upward trend in the presence of MOLT-4 cells plus BM-MSC. The co-culture of leukemia cells with BMMSCs under hypoxic conditions may be a potential therapeutic approach for ALL.
Literatur
1.
Zhou L, Wang M, Li A. Analysis of risk factors of peripherally inserted central catheter induced catheter-related infection in patients with Leukemia. Iran J Public Health. 2017;46:485–90.PubMedPubMedCentral
2.
Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855–68.PubMedCrossRef
3.
Yazdi MH, Faramarzi MA, Nikfar S, Abdollahi M. Comparative safety and efficacy of tyrosine kinase inhibitors (TKIs) in the treatment setting of different types of leukemia, and different types of adenocarcinoma. Biomed Pharmacother. 2017;95:1556–64.PubMedCrossRef
4.
Short NJ, Jabbour E, Albitar M, de Lima M, Gore L, Jorgensen J, Logan AC, Park J, Ravandi F, Shah B, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. Am J Hematol. 2018;94:257–65.PubMedPubMedCentralCrossRef
5.
Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, Cornelissen JJ, Doubek M, Esteve J, Fielding A, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2018;54:798–809.PubMedCrossRef
6.
Marofi F, Vahedi G, Hasanzadeh A, Salarinasab S, Arzhanga P, Khademi B, Farshdousti Hagh M. Mesenchymal stem cells as the game-changing tools in the treatment of various organs disorders: mirage or reality? J Cell Physiol. 2018;234:1268–88.PubMedCrossRef
7.
Devireddy LR, Boxer L, Myers MJ, Skasko M, Screven R. Questions and challenges in the development of mesenchymal stromal/stem cell-based therapies in veterinary medicine. Tissue Eng Part B Rev. 2017;23:462–70.PubMedCrossRef
8.
Marofi F, Vahedi G, Biglari A, Esmaeilzadeh A, Athari SS. Mesenchymal stromal/stem cells: a new era in the cell-based targeted gene therapy of cancer. Front Immunol. 2017;8:1770.PubMedPubMedCentralCrossRef
9.
Dianat-Moghadam H, Rokni M, Marofi F, Panahi Y, Yousefi M. Natural killer cell–based immunotherapy: from transplantation toward targeting cancer stem cells. J Cell Physiol. 2019;234:259–73.CrossRef
10.
Gregory CA, Ylostalo J, Prockop DJ. Adult bone marrow stem/progenitor cells (MSCs) are preconditioned by microenvironmental “niches” in culture: a two-stage hypothesis for regulation of MSC fate. Sci STKE. 2005;2005:pe37.PubMedCrossRef
11.
Wu T, Liu Y, Wang B, Li G. The roles of mesenchymal stem cells in tissue repair and disease modification. Curr Stem Cell Res Ther. 2014;9:424–31.PubMedCrossRef
12.
Zhan J, Li Y, Yu J, Zhao Y, Cao W, Ma J, Sun X, Sun L, Qian H, Zhu W, Xu W. Culture medium of bone marrow-derived human mesenchymal stem cells effects lymphatic endothelial cells and tumor lymph vessel formation. Oncol Lett. 2015;9:1221–6.PubMedPubMedCentralCrossRef
13.
Baharaghdam S, Yousefi M, Movasaghpour A, Solali S, Talebi M, Ahani-Nahayati M, Lotfimehr H, Shamsasanjan K. Effects of hypoxia on biology of human leukemia T-cell line (MOLT-4 cells) co-cultured with bone marrow mesenchymal stem cells. Avicenna J Med Biotechnol. 2018;10:62–8.PubMedPubMedCentral
14.
Corradi G, Baldazzi C, Ocadlikova D, Marconi G, Parisi S, Testoni N, Finelli C, Cavo M, Curti A, Ciciarello M. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. Stem Cell Res Ther. 2018;9:271.PubMedPubMedCentralCrossRef
15.
Ejtehadifar M, Shamsasenjan K, Akbarzadehlaleh P, Zahedi S, Kazemi N. The effects of hypoxia on U937 cell line in mesenchymal stem cells co-culture system. Adv Pharm Bull. 2016;6:645–50.PubMedPubMedCentralCrossRef
16.
Stothers CL, Luan L, Fensterheim BA, Bohannon JK. Hypoxia-inducible factor-1alpha regulation of myeloid cells. J Mol Med (Berl). 2018;96:1293–306.CrossRef
17.
18.
Drolle H, Wagner M, Vasold J, Kutt A, Deniffel C, Sotlar K, Sironi S, Herold T, Rieger C, Fiegl M. Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. Leuk Res. 2015;39:779–85.PubMedCrossRef
19.
Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Can Res. 2006;66:6264–70.CrossRef
20.
Casciello F, Al-Ejeh F, Kelly G, Brennan DJ, Ngiow SF, Young A, Stoll T, Windloch K, Hill MM, Smyth MJ, et al. G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. Proc Natl Acad Sci. 2017;114:7077–82.PubMedPubMedCentralCrossRef
21.
Aldo P, Elisabetta C. Role of HIF-1 in cancer progression: novel insights. A review. Curr Mol Med. 2018;18(6):343–51.
22.
Suzuki N, Vojnovic N, Lee K-L, Yang H, Gradin K, Poellinger L. HIF-dependent and reversible nucleosome disassembly in hypoxia-inducible gene promoters. Exp Cell Res. 2018;366:181–91.PubMedCrossRef
23.
Nam HJ, Baek SH. Epigenetic regulation of the hypoxic response. Curr Opin Physio. 2019;7:1–8.CrossRef
24.
25.
Elkhouly E, Samir A, Alkady N. Expression of Her2-neu, SKP2 and HIF-1 and their role in predicting the response of muscle invasive urothelial carcinoma to bladder- preservation chemotherapy. Eur Urol Suppl. 2018;17:e2965.CrossRef
26.
27.
Lee Y, Lim HS. Skp2 inhibitors: novel anticancer strategies. Curr Med Chem. 2016;23:2363–79.PubMedCrossRef
28.
Kim H, Kim D, Choi SA, Kim CR, Oh SK, Pyo KE, Kim J, Lee S-H, Yoon J-B, Zhang Y, Baek SH. KDM3A histone demethylase functions as an essential factor for activation of JAK2−STAT3 signaling pathway. Proc Natl Acad Sci. 2018;115:11766–71.PubMedPubMedCentralCrossRef
29.
30.
Breig O, Bras S, Martinez Soria N, Osman D, Heidenreich O, Haenlin M, Waltzer L. Pontin is a critical regulator for AML1-ETO-induced leukemia. Leukemia. 2013;28:1271.PubMedCrossRef
31.
Zhang B-F, Jiang H, Chen J, Guo X, Hu Q, Yang S. KDM3A inhibition attenuates high concentration insulin-induced vascular smooth muscle cell injury by suppressing MAPK/NF-κB pathways. Int J Mol Med. 2018;41:1265–74.PubMed
32.
Park JW, Cho H, Oh H, Kim JY, Seo SB. AURKA suppresses leukemic THP-1 cell differentiation through inhibition of the KDM6B pathway. Mol Cells. 2018;41:444–53.PubMedPubMedCentral
33.
Wang L-X, Wang J-D, Chen J-J, Long B, Liu L-L, Tu X-X, Luo Y, Hu Y, Lin D-J, Lu G, et al. Aurora A kinase inhibitor AKI603 induces cellular senescence in chronic myeloid leukemia cells harboring T315I mutation. Sci Rep. 2016;6:35533.PubMedPubMedCentralCrossRef
34.
Wang D, Qin H, Du W, Shen Y-W, Lee W-H, Riggs AD, Liu C-P. Inhibition of S-phase kinase-associated protein 2 (Skp2) reprograms and converts diabetogenic T cells to Foxp3<sup>+</sup> regulatory T cells. Proc Natl Acad Sci. 2012;109:9493–8.PubMedPubMedCentralCrossRef
35.
Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 2015;3:356–67.PubMedPubMedCentralCrossRef
36.
Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, Heyman M, Jonmundsson G, Kanerva J, Schmiegelow K, et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood. 2010;115:1214–25.PubMedCrossRef
37.
Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-Bucktrout S, Anthony BA, Sverdrup FM, Head R, Kuster DJ, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012;209(1713–1722):s1711-1719.
38.
Zhuo C, Li Z, Xu Y, Wang Y, Li Q, Peng J, Zheng H, Wu P, Li B, Cai S. Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival. Mol Cancer. 2014;13:153.PubMedPubMedCentralCrossRef
39.
Marofi F, Vahedi G, Solali S, Alivand M, Salarinasab S, Zadi Heydarabad M, Farshdousti Hagh M. Gene expression of TWIST1 and ZBTB16 is regulated by methylation modifications during the osteoblastic differentiation of mesenchymal stem cells. J Cell Physiol. 2018;234:6230.PubMedCrossRef
40.
Tan K, Peng YT, Guo P. MiR-29a promotes osteogenic differentiation of mesenchymal stem cells via targeting HDAC4. Eur Rev Med Pharmacol Sci. 2018;22:3318–26.PubMed
41.
Hong I-S, Lee H-Y, Kang K-S. Mesenchymal stem cells and cancer: friends or enemies? Mutation Res/Fundam Mol Mech Mutagen. 2014;768:98–106.CrossRef
42.
Lee MW, Park YJ, Kim DS, Park HJ, Jung HL, Lee JW, Sung KW, Koo HH, Yoo KH. Human adipose tissue stem cells promote the growth of acute lymphoblastic leukemia cells in NOD/SCID mice. Stem Cell Rev. 2018;14:451–60.CrossRef
43.
44.
Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo V, Ishizawa J, et al. Bone marrow adipocytes facilitate fatty acid oxidation activating AMPK and a transcriptional network supporting survival of acute monocytic leukemia cells. Cancer Res. 2017;77:1453–64.PubMedPubMedCentralCrossRef
45.
Brenner AK, Nepstad I, Bruserud O. Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms. Front Immunol. 2017;8:106.PubMedPubMedCentralCrossRef
46.
Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 2004;18:2183–94.PubMedPubMedCentralCrossRef
47.
Seifi S, Khatony A, Moradi G, Abdi A, Najafi F. Accuracy of pulse oximetry in detection of oxygen saturation in patients admitted to the intensive care unit of heart surgery: comparison of finger, toe, forehead and earlobe probes. BMC Nurs. 2018;17:15–15.PubMedPubMedCentralCrossRef
48.
Hung SP, Yang MH, Tseng KF, Lee OK. Hypoxia-induced secretion of TGF-beta1 in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant. 2013;22:1869–82.PubMedCrossRef
49.
Song SW, Kim KE, Choi JW, Lee CY, Lee J, Seo HH, Lim KH, Lim S, Lee S, Kim SW, Hwang KC. Proteomic Analysis and Identification of Paracrine Factors in Mesenchymal Stem Cell-Conditioned Media under Hypoxia. Cell Physiol Biochem. 2016;40:400–10.PubMedCrossRef
50.
Kumar S, Vaidya M. Hypoxia inhibits mesenchymal stem cell proliferation through HIF1alpha-dependent regulation of P27. Mol Cell Biochem. 2016;415:29–38.PubMedCrossRef
51.
52.
Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117:1049–57.PubMedPubMedCentralCrossRef
53.
Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updates. 2009;12:103–13.CrossRef
54.
Ahani-Nahayati M, Solali S, Shams Asenjan K, Movassaghpour Akbari AA, Talebi M, Zadi Heydarabad M, Baharaghdam S, Farshdousti Hagh M. Promoter methylation status of survival-related genes in MOLT-4 cells co-cultured with bone marrow mesenchymal stem cells under hypoxic conditions. Cell J. 2018;20:188–94.PubMedPubMedCentral
55.
56.
Cholewa-Waclaw J, Bird A, von Schimmelmann M, Schaefer A, Yu H, Song H, Madabhushi R, Tsai L-H. The role of epigenetic mechanisms in the regulation of gene expression in the nervous system. J Neurosci Off J Soc Neurosci. 2016;36:11427–34.CrossRef
57.
Huang Z, Huang Q, Ji L, Wang Y, Qi X, Liu L, Liu Z, Lu L. Epigenetic regulation of active Chinese herbal components for cancer prevention and treatment: a follow-up review. Pharmacol Res. 2016;114:1–12.PubMedCrossRef
58.
59.
Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487–94.PubMedCrossRef
60.
Ntziachristos P, Mullenders J, Trimarchi T, Aifantis I. Mechanisms of epigenetic regulation of leukemia onset and progression. Adv Immunol. 2013;117:1–38.PubMedCrossRef
61.
Haladyna JN, Yamauchi T, Neff T, Bernt KM. Epigenetic modifiers in normal and malignant hematopoiesis. Epigenomics. 2015;7:301–20.PubMedCrossRef
62.
63.
Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li Y, Xu C, Ouyang G, Duan S. The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. PLoS ONE. 2014;9:e96822–e96822.PubMedPubMedCentralCrossRef
64.
Zhang Y-B, Wang X, Meister EA, Gong K-R, Yan S-C, Lu G-W, Ji X-M, Shao G. The effects of CoCl2 on HIF-1α protein under experimental conditions of autoprogressive hypoxia using mouse models. Int J Mol Sci. 2014;15:10999–1012.PubMedPubMedCentralCrossRef
Metadaten
Titel
Expression of proliferation-related genes in BM-MSC-treated ALL cells in hypoxia condition is regulated under the influence of epigenetic factors in-vitro
verfasst von
Xiaoyu Yang
Yan Wang
Heshu Sulaiman Rahman
Talar Ahmad Merza Mohammad
Amin Daei Sorkhabi
Stanislav Evgenievich Korsakov
Lakshmi Thangavelu
Ali Adili
Aila Sarkesh
Rozita Tamjidifar
Hossein Saeedi
Ramin Aslaminabad
Saeed Tarzi
Morteza Akbari
Publikationsdatum
01.07.2022
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 7/2022
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-022-01671-6

Weitere Artikel der Ausgabe 7/2022

Medical Oncology 7/2022 Zur Ausgabe

Original Paper

Combinational treatment of TPEN and TPGS induces apoptosis in acute lymphoblastic and chronic myeloid leukemia cells in vitro and ex vivo

Original Paper

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers

Review Article

The role of histone deacetylase 3 in breast cancer

Original Paper

Long non-coding RNA AC245100.4 contributes to prostate cancer migration via regulating PAR2 and activating p38-MAPK pathway

Original Paper

Tumor-associated macrophages of the M1/M2 phenotype are involved in the regulation of malignant biological behavior of breast cancer cells through the EMT pathway

Original Paper

Engineering tumor-derived small extra cellular vesicles to encapsulate miR-34a, effectively inhibits 4T1 cell proliferation, migration, and gene expression

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise